Clinical trials: Acute Phase Response
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Acute Myeloid Leukemia
Timed-Sequential Induction in CBF-AML
Core binding factor (CBF) acute myeloid leukemias (AML) include AMLs carrying the t(8;21) translocation as well as AMLs carrying either the inversion of chromosome 16 or translocation t(16;16).
- Trial name
- NCT00428558
- Testing
- Chemotherapy (DAUNORUBICINE-CYTARABINE)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Sepsis, Acute Lung Injury
Citrulline in Severe Sepsis
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or…
- Trial name
- NCT01474863
- Testing
- High Dose Citrulline, Low Dose Citrulline
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Vanderbilt University
Graft Vs Host Disease
A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
This is an academic open-label, phase II randomized study in patients with steroid resistant severe acute Graft versus host disease (GvHD) who have had allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05132166
- Testing
- Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib., Decidual Stromal Cells
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Renal Disease
Acute Physiological Response to Exercise in End Stage Renal Disease
Chronic kidney disease (CKD) affects between 5-10% of the world's population, equating to ~740 million people worldwide. End stage renal disease (ESRD) is the result of a progressive loss of kidney function where the patient…
- Trial name
- PRECISE (NCT03064555)
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Coventry University
Hypertension, Pulmonary
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT00853112
- Testing
- PF-00489791, sildenafil
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
The Primary Condition Studied for This Trial is Acute Stress
Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress
The objective of the STRESS trial is to investigate in a mode of action setting the effect of Zeller Entspannung film coated tablets on saliva cortisol response versus Placebo after acute stress in healthy male volunteers.
- Trial name
- NCT02189239
- Testing
- Zeller Entspannung film coated tablet, No Treatment
- Where
- Switzerland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Max Zeller Soehne AG
Systemic Inflammatory Response Syndrome, Coronary Artery Bypass Grafting
Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)
EA-230 is a newly developed synthetic compound with anti-inflammatory properties, it is a linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG).
- Trial name
- EASI (NCT03145220)
- Testing
- EA-230
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Radboud University Medical Center
Periodontitis, Hypertension
Acute-phase Response & Periodontal Treatment in Patients With Hypertension
The aim of this study is to compare quadrant scaling and root planing (Q-SRP) versus full-mouth treatment (FM-SRP) in terms of acute-phase responses following non surgical periodontal treatment in patients affected by…
- Trial name
- PERIO-HYPERTEN (NCT03122990)
- Testing
- FM-SRP, Q-SRP
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Pisa
Periodontal Diseases
Acute Phase Response & Periodontal Treatment
This study has compared quadrant scaling and root planing (Q-SRP) versus intensive treatment performed within 24 hours (FM-SRP) in terms of acute phase responses following treatment of periodontal disease.
- Trial name
- PERIOSYST-1 (NCT02460926)
- Testing
- Scaling & Root Planing
- Volunteers
- 38 people
- Sponsor
- University of Pisa
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA-BLIN-01/PET069014 (BLIN-01)
The PETHEMA Spanish group treats patients with high-risk Philadelphia chromosome-negative ALL, aged 18 to 55 years, based on the MRD clearance as assessed by flow cytometry at a centralised evaluation centre.
- Trial name
- NCT03523429
- Testing
- blinatumomab
- Where
- 12 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT00276159
- Testing
- 852A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Sepsis
The Degree, Duration and Frequency of Insulin Resistance in Non-operated Patients With Sepsis
Surgery induces insulin resistance lasting for 2-3 weeks. We wanted to elucidate if stress-metabolic, medical conditions carry the same effect.
- Trial name
- NCT04969159
- Testing
- no intervention
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Jens Rikardt Andersen
Multiple Organ Failure, End Stage Cardiac Failure
Timing of Acute Palliative Care Consultation in Critically Ill Patients
A prospective randomized controlled trial studying the ordering of palliative care consultations in the emergency department (Ig) versus later palliative care consultations in the hospital--ICU or hospital ward(Cg).
- Conditions
- Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5
- Trial name
- NCT02858778
- Testing
- Early order of palliative care consultation
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wayne State University
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response…
- Trial name
- NCT05138822
- Testing
- GSK3882347, Nitrofurantoin
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Leukemia
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
The extension study followed the core study CAMN107ECN02 (NCT01275196). which is an open-label, two armed study. All patients enrolled in this extension study were able to benefit from the treatment given in CAMN107ECN02 per…
- Trial name
- NCT02272777
- Testing
- Imatinib, Nilotinib
- Where
- 12 sites in China
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids.
- Trial name
- NCT01863186
- Testing
- Lofexidine HCl, Open Label Lofexidine HCL
- Where
- 18 sites in United States
- Volunteers
- 603 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
RATIONALE: The influenza vaccine may help prevent flu in patients who have undergone stem cell transplant. PURPOSE: This clinical trial is studying how well the influenza vaccine works in preventing flu in patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00952185
- Testing
- cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
HIV
A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004
The purpose of this study is to: find out the intensity and duration of the immune response after multiple injections of the investigational study product AGS-004 made from one's own dendritic cells and one's own strain of HIV…
- Trial name
- NCT02042248
- Testing
- AGS-004
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cynthia L Gay, MD